Adocia has launched a phase IIa clinical trial on its ultra-fast acting formulation of insulin Lispro (Humalog(R), Eli Lilly) using its proprietary technology BioChaperone(R)). This clinical trial aims to demonstrate that the BioChaperone Lispro formulation acts faster than Humalog, which would allow patients to achieve a better glycemic control after a meal. During this study, pharmacodynamic and pharmacokinetic profiles of the BioChaperone Lispro formulation will be compared to those of Humalog in a cross-over design on 36 type I diabetic patients under euglycemic clamp.

The first patients of this double-blind study conducted by Profil, a German CRO specialized in diabetes, have already been treated. Results from this study are expected during the second quarter of 2014. Adocia is therefore entering the second stage of the clinical development plan of its ultra-fast acting analog insulin.

During the first phase I clinical study, performed by Eli Lilly on healthy volunteers, the BioChaperone Lispro formulation reached all its predefined clinical endpoints.